News | August 08, 2025
Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The submission is supported by positive results from the Phase 3 AMPLIFY trial
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Subscribe To Our Newsletter & Stay Updated
